Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
19.99
+0.12 (0.60%)
At close: Mar 28, 2025, 4:00 PM
19.86
-0.13 (-0.65%)
After-hours: Mar 28, 2025, 4:54 PM EDT

Dianthus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.242.836.421.48
Revenue Growth (YoY)
120.63%-55.96%334.76%-
Gross Profit
6.242.836.421.48
Selling, General & Admin
24.9918.166.741.96
Research & Development
83.1132.8429.3812.61
Operating Expenses
108.15136.1214.56
Operating Income
-101.86-48.17-29.71-13.09
Interest & Investment Income
17.374.761.150
Currency Exchange Gain (Loss)
-0.06-0.090.14-0.03
Other Non Operating Income (Expenses)
-0.55-0.06-0.05-
EBT Excluding Unusual Items
-85.12-43.56-28.48-13.11
Gain (Loss) on Sale of Investments
0.15---
Pretax Income
-84.97-43.56-28.48-13.11
Net Income
-84.97-43.56-28.48-13.11
Net Income to Common
-84.97-43.56-28.48-13.11
Shares Outstanding (Basic)
33514
Shares Outstanding (Diluted)
33514
Shares Change (YoY)
546.44%489.48%-78.17%-
EPS (Basic)
-2.55-8.45-32.57-3.27
EPS (Diluted)
-2.55-8.45-32.57-3.27
Free Cash Flow
-78.29-36.97-29.21-9.94
Free Cash Flow Per Share
-2.35-7.17-33.41-2.48
Gross Margin
100.00%100.00%100.00%100.00%
Operating Margin
-1633.75%-1704.67%-462.91%-886.59%
Profit Margin
-1362.78%-1541.22%-443.76%-888.14%
Free Cash Flow Margin
-1255.57%-1308.24%-455.18%-673.24%
EBITDA
-101.77-48.11-29.68-
D&A For EBITDA
0.10.070.03-
EBIT
-101.86-48.17-29.71-13.09
Revenue as Reported
6.242.83--
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q